管理多发性硬化症患者可改变的合并症的重要性:一项叙述性综述
The Importance of Managing Modifiable Comorbidities in People with Multiple Sclerosis: A Narrative Review.
作者信息
Nociti Viviana, Romozzi Marina
机构信息
Centro Sclerosi Multipla, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
出版信息
J Pers Med. 2023 Oct 24;13(11):1524. doi: 10.3390/jpm13111524.
Multiple sclerosis (MS) is a chronic, inflammatory, degenerative demyelinating disease of the central nervous system (CNS) of unknown etiology that affects individuals in their early adulthood. In the last decade, life expectancy for people with MS (PwMS) has almost equaled that of the general population. This demographic shift necessitates a heightened awareness of comorbidities, especially the ones that can be prevented and modified, that can significantly impact disease progression and management. Vascular comorbidities are of particular interest as they are mostly modifiable health states, along with voluntary behaviors, such as smoking and alcohol consumption, commonly observed among individuals with MS. Vascular risk factors have also been implicated in the etiology of cerebral small vessel disease. Furthermore, differentiating between vascular and MS lesion load poses a significant challenge due to overlapping clinical and radiological features. This review describes the current evidence regarding the range of preventable and modifiable comorbidities and risk factors and their implications for PwMS.
多发性硬化症(MS)是一种病因不明的中枢神经系统(CNS)慢性、炎症性、退行性脱髓鞘疾病,主要影响成年早期个体。在过去十年中,多发性硬化症患者(PwMS)的预期寿命几乎与普通人群相当。这种人口结构的变化使得人们必须更加关注合并症,尤其是那些可以预防和改善的合并症,因为它们会对疾病的进展和管理产生重大影响。血管合并症尤其值得关注,因为它们大多是可改善的健康状况,同时还有一些在MS患者中常见的自愿行为,如吸烟和饮酒。血管危险因素也与脑小血管疾病的病因有关。此外,由于临床和放射学特征重叠,区分血管病变和MS病变负荷是一项重大挑战。本综述描述了关于可预防和可改善的合并症及危险因素范围的现有证据及其对PwMS的影响。
相似文献
J Pers Med. 2024-4-10
Mult Scler Relat Disord. 2022-12
J Pers Med. 2022-11-3
Neurol Neuroimmunol Neuroinflamm. 2022-3
Front Neurol. 2020-8-21
Geriatrics (Basel). 2022-6-5
引用本文的文献
J Pers Med. 2024-4-10
本文引用的文献
Int J Mol Sci. 2023-5-8
J Pers Med. 2022-11-3
Neurodegener Dis Manag. 2023-2
Mult Scler. 2021-12